MILFORD, Mass., May 11, 2011 /PRNewswire/ -- SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences companyproviding vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today announced the election of Joseph Nemmers and Kevin Hrusovsky
(Logo: http://photos.prnewswire.com/prnh/20110324/NE70714LOGO )
"Kevin and Joe are excellent strategic additions to the Board," said Susan Vogt, President and Chief Executive Officer of SeraCare. "We welcome them to SeraCare's Board of Directors and look forward to their participation in helping the Company reach its next level of success. I would also like to thank Samuel Anderson, Harold Blue and Eugene Davis, who are retiring from the Board, for their service over the years and the role they played in helping to transform SeraCare into a profitable company with a promising future."
"SeraCare's growing product portfolio and blue chip customer base position them as leaders in the sector while also presenting significant opportunities for future growth," said Mr. Nemmers. "I am pleased to join the Board and look forward to working with SeraCare to advance their business model and expand their market reach."
Joseph M. Nemmers brings to the Board extensive executive level experience in in vitro diagnostic, pharmaceutical and medical device operations. Mr. Nemmers retired from Abbott Laboratories in 2007 after 27 years of service. His most recent position with Abbott was Executive Vice President responsible for five of Abbott's medical products businesses. Since August 2010, Mr. Nemmers has maintained a consulting practice serving the pharmaceutical and medical device industries, advising on acquisition integration, change management, supply chain readiness and talent development. Mr. Nemmers is currently a member of the board of directors of Nexus DX, a New Jersey-based clinical diagnostics company and of Advocate Condell Medical Center and the Advocate Charitable Foundation, both headquartered in Illinois. Mr. Nemmers holds a B.S. from Arizona State University and is a former commissioned officer in the United States Army Reserve where he served for 13 years.
E. Kevin Hrusovsky brings to the Board experience serving as a director and in leadership positions of other publicly held companies, particularly in the life sciences industry, as well as experience with turnarounds, commercialization, mergers and acquisitions. Mr. Hrusovsky currently serves as President, Chief Executive Officer and Director of Caliper Life Sciences, Inc. He served in the same capacity at Zymark Corporation until July 2003 when Zymark was acquired by Caliper. In addition, he has held senior level roles at FMC Corporation and E.I. DuPont de Nemours. Mr. Hrusovsky currently sits on Caliper's Board of Directors, as well as on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation and the Strategy Committee of Children's Hospital Boston. Mr. Hrusovsky received his B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University.
About SeraCare Life Sciences, Inc.:
SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry. www.seracare.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our business strategy, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these expectations will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, prolonged impairment of sales from changes in our sales organization, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.
Contacts: Gregory A. GouldChief Financial Officer SeraCare Life Sciences, Inc.508-244-6400Sarah CavanaughMacDougall Biomedical Communications781-235-3060
SOURCE SeraCare Life Sciences, Inc.
Subscribe to our Free Newsletters!
Adult immunization is needed for adults whose mandatory childhood vaccines were either missed out ...
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast ...View All